These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 9737398)

  • 1. Quality of biotechnological products: stability testing of biotechnological/biological products. Annex to the ICH Harmonised Tripartite Guideline for the Stability Testing of New Drug Substances and Products.
    Dev Biol Stand; 1998; 93():211-9. PubMed ID: 9737398
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():205-8. PubMed ID: 9737397
    [No Abstract]   [Full Text] [Related]  

  • 3. Quality of biotechnological products: derivation and characterisation of cell substrates used for production of biotechnological/biological products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():223-34. PubMed ID: 9737399
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396
    [No Abstract]   [Full Text] [Related]  

  • 5. Stability testing requirements for vaccines--draft guidelines of the International Conference on Harmonization.
    Haase M
    Dev Biol Stand; 1996; 87():309-18. PubMed ID: 8854031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The quality control of biotechnology products.
    Federici MM
    Biologicals; 1994 Jun; 22(2):151-9. PubMed ID: 7917231
    [No Abstract]   [Full Text] [Related]  

  • 7. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current practices in endotoxin and pyrogen testing in biotechnology. The Quality Assurance/Quality Control Task Group. Parenteral Drug Association.
    J Parenter Sci Technol; 1990; 44(1):39-45. PubMed ID: 2313492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of compounding on sterility and stability of drugs.
    Hardee GE
    J Am Vet Med Assoc; 1994 Jul; 205(2):224-5. PubMed ID: 7928582
    [No Abstract]   [Full Text] [Related]  

  • 13. ICH guidelines and PhEur monographs on derivation and characterisation of cell substrates used for production of biotechnological/biological products. International Conference on Harmonisation.
    Dobbelaer R
    Dev Biol Stand; 1999; 98():159-65; discussion 167. PubMed ID: 10494969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CBER status on reform initiatives: industry reactions and comments.
    Page M
    Food Drug Law J; 1997; 52(2):193-6. PubMed ID: 10557559
    [No Abstract]   [Full Text] [Related]  

  • 15. [Importance of control tests of biological products in relation to the use in practice].
    Fernández de Castro J
    Salud Publica Mex; 1979; 21(4):361-8. PubMed ID: 550315
    [No Abstract]   [Full Text] [Related]  

  • 16. International Conference on Harmonisation: guidance on Q1D bracketing and matrixing designs for stability testing of new drug substances and products; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jan; 68(11):2339-40. PubMed ID: 12532979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated degradation testing.
    Fágáin CO; Sheehan H; O'Kennedy R
    Am Biotechnol Lab; 1991 Oct; 9(9):31-2. PubMed ID: 1367562
    [No Abstract]   [Full Text] [Related]  

  • 18. Laboratory tests on the stability of biological reference preparations.
    Kirkwood TB
    Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M; 1987; (80):289-96. PubMed ID: 3688870
    [No Abstract]   [Full Text] [Related]  

  • 19. Well-characterized biotechnology products: evolving to meet the needs of the 21st century.
    Zoon KC
    Dev Biol Stand; 1998; 96():3-8. PubMed ID: 9890510
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of biotechnology products.
    Tami J; Evens RP
    Pharmacotherapy; 1996; 16(4):527-36. PubMed ID: 8840359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.